Identification and Characterization of CDH1 Germline Variants in Sporadic Gastric Cancer Patients and in Individuals at Risk of Gastric Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Nov 9

PMID 24204729

Citations 17

Authors

Marica Garziera

Vincenzo Canzonieri

Renato Cannizzaro

Silvano Geremia

Laura Caggiari

Mariangela De Zorzi

Stefania Maiero

Enrico Orzes

Tiziana Perin

Stefania Zanussi

Paolo de Paoli

Valli De Re

Affiliations

Soon will be listed here.

Abstract

Objective: To screen and characterize germline variants for E-cadherin (CDH1) in non-hereditary gastric cancer (GC) patients and in subjects at risk of GC.

Methods: 59 GCs, 59 first degree relatives (FDRs) of GC, 20 autoimmune metaplastic atrophic gastritis (AMAGs) and 52 blood donors (BDs) were analyzed for CDH1 by direct sequencing, structural modelling and bioinformatics. Functional impact on splicing was assessed for intronic mutations. E-cadherin/β-catenin immunohistochemical staining and E-cadherin mRNA quantification using RT-PCR were performed.

Results: In GCs, 4 missense variants (p.G274S; p.A298T; p.T470I; p.A592T), 1 mutation in the 5'UTR (-71C>G) and 1 mutation in the intronic IVS12 (c.1937-13T>C) region were found. First pathogenic effect of p.A298T mutation was predicted by protein 3D modelling. The novel p.G274S mutation showed a no clear functional significance. Moreover, first, intronic IVS12 (c.1937-13T>C) mutation was demonstrated to lead to an aberrant CDH1 transcript with exon 11 deletion. This mutation was found in 2 GCs and in 1 BD. In FDRs, we identified 4 variants: the polymorphic (p.A592T) and 3 mutations in untranslated regions with unidentified functional role except for the 5'UTR (-54G>C) that had been found to decrease CDH1 transcription. In AMAGs, we detected 2 alterations: 1 missense (p.A592T) and 1 novel variant (IVS1 (c.48+7C>T)) without effect on CDH1 splicing. Several silent and polymorphic substitutions were found in all the groups studied.

Conclusions: Overall our study improves upon the current characterization of CDH1 mutations and their functional role in GC and in individuals at risk of GC. Mutations found in untranslated regions and data on splicing effects deserve a particular attention like associated with a reduced E-cadherin amount. The utility of CDH1 screening, in addition to the identification of other risk factors, could be useful for the early detection of GC in subjects at risk (i.e. FDRs and AMAGs), and warrants further study.

Citing Articles

Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration.

Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L Int J Mol Sci. 2024; 25(5).

PMID: 38473896 PMC: 10931799. DOI: 10.3390/ijms25052649.

Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions.

Businello G, Angerilli V, Parente P, Realdon S, Savarino E, Farinati F Int J Mol Sci. 2021; 22(18).

PMID: 34576114 PMC: 8468646. DOI: 10.3390/ijms22189950.

Correlation of -160C > A and -347GA > G polymorphisms in E-cadherin gene and gastric cancer in north of Iran.

Shekarriz R, Alikhani R, Ghasemi M, Navaei R, Hashemi-Soteh M J Res Med Sci. 2021; 26:3.

PMID: 34084182 PMC: 8103955. DOI: 10.4103/jrms.JRMS_50_20.

Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin.

Forster A, Brand F, Banan R, Huneburg R, Weber C, Ewert W Acta Neuropathol. 2021; 142(1):191-210.

PMID: 33929593 PMC: 8217027. DOI: 10.1007/s00401-021-02307-1.

Geographical Distribution of E-cadherin Germline Mutations in the Context of Diffuse Gastric Cancer: A Systematic Review.

Corso G, Corso F, Bellerba F, Carneiro P, Seixas S, Cioffi A Cancers (Basel). 2021; 13(6).

PMID: 33809393 PMC: 8001745. DOI: 10.3390/cancers13061269.

References

Nakamura A, Shimazaki T, Kaneko K, Shibata M, Matsumura T, Nagai M . Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res. 2002; 502(1-2):19-24. DOI: 10.1016/s0027-5107(02)00024-6. View

Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel M . Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007; 44(11):726-31. PMC: 2752184. DOI: 10.1136/jmg.2007.051268. View

Barber M, Fitzgerald R, Caldas C . Familial gastric cancer - aetiology and pathogenesis. Best Pract Res Clin Gastroenterol. 2006; 20(4):721-34. DOI: 10.1016/j.bpg.2006.03.014. View

Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P . E-cadherin germline mutations in familial gastric cancer. Nature. 1998; 392(6674):402-5. DOI: 10.1038/32918. View

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

Perri F, Cotugno R, Piepoli A, Merla A, Quitadamo M, Gentile A . Aberrant DNA methylation in non-neoplastic gastric mucosa of H. Pylori infected patients and effect of eradication. Am J Gastroenterol. 2007; 102(7):1361-71. DOI: 10.1111/j.1572-0241.2007.01284.x. View

Guilford P, Blair V, More H, Humar B . A short guide to hereditary diffuse gastric cancer. Hered Cancer Clin Pract. 2009; 5(4):183-94. PMC: 2736978. DOI: 10.1186/1897-4287-5-4-183. View

Suriano G, Oliveira C, Ferreira P, Machado J, Bordin M, de Wever O . Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet. 2003; 12(5):575-82. DOI: 10.1093/hmg/ddg048. View

Risinger J, Berchuck A, Kohler M, Boyd J . Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 1994; 7(1):98-102. DOI: 10.1038/ng0594-98. View

10.

De Re V, Cannizzaro R, Canzonieri V, Cecchin E, Caggiari L, De Mattia E . MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer. Tumour Biol. 2010; 31(1):23-32. PMC: 2803747. DOI: 10.1007/s13277-009-0004-1. View

11.

Harrison O, Bahna F, Katsamba P, Jin X, Brasch J, Vendome J . Two-step adhesive binding by classical cadherins. Nat Struct Mol Biol. 2010; 17(3):348-57. PMC: 2872554. DOI: 10.1038/nsmb.1784. View

12.

Graziano F, Arduini F, Ruzzo A, Mandolesi A, Bearzi I, Silva R . Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol. 2004; 15(3):489-92. DOI: 10.1093/annonc/mdh108. View

13.

Mateus A, Simoes-Correia J, Figueiredo J, Heindl S, Alves C, Suriano G . E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res. 2009; 315(8):1393-402. DOI: 10.1016/j.yexcr.2009.02.020. View

14.

Harrison O, Jin X, Hong S, Bahna F, Ahlsen G, Brasch J . The extracellular architecture of adherens junctions revealed by crystal structures of type I cadherins. Structure. 2011; 19(2):244-56. PMC: 3070544. DOI: 10.1016/j.str.2010.11.016. View

15.

Garziera M, De Re V, Geremia S, Seruca R, Figueiredo J, Melo S . A novel CDH1 germline missense mutation in a sporadic gastric cancer patient in north-east of Italy. Clin Exp Med. 2012; 13(2):149-57. DOI: 10.1007/s10238-012-0184-7. View

16.

Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A . E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2010; 47(4):631-9. DOI: 10.1016/j.ejca.2010.10.011. View

17.

Perl A, Wilgenbus P, Dahl U, Semb H, Christofori G . A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998; 392(6672):190-3. DOI: 10.1038/32433. View

18.

Berx G, Becker K, Hofler H, VAN Roy F . Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998; 12(4):226-37. DOI: 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D. View

19.

Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P . Regional estimates of stomach cancer burden in Italy. Tumori. 2007; 93(4):367-73. DOI: 10.1177/030089160709300407. View

20.

Strumane K, Berx G, VAN Roy F . Cadherins in cancer. Handb Exp Pharmacol. 2010; (165):69-103. DOI: 10.1007/978-3-540-68170-0_4. View